Quantum Biopharma completes dosing in Lucid-MS studies

Mr. Zeeshan Saeed reports QUANTUM BIOPHARMA ANNOUNCES COMPLETION OF DOSING IN 180-DAY REPEATED DOSE ORAL TOXICITY AND TOXICOKINETIC STUDIES FOR LUCID-21-302 (LUCID-MS) Quantum Biopharma Ltd. has completed oral dosing of Lucid-21-302 (Lucid-MS) in both the 180-day toxicity and toxicokinetic studies. These studies will support the investigational new drug (IND) application with the U.S. Food and Drug Administration, including the design of a phase 2 trial of Lucid-MS in people with multiple sclerosis (MS). "We are very pleased that dosing is now complete in both 180-day chronic toxicity studies. These studies allow us to advance the Lucid-MS drug development program as they are critical components to the IND application with the FDA," said Dr. Andrzej Chruscinski, vice-president, scientific and clinical affairs, at Quantum Biopharma. Anthony Durkacz, founder and executive co-chairman of Quantum Biopharma, added: "By completing these 180-day toxicity studies, we are now two important steps closer to initiating the phase 2 trial of Lucid-MS in people with multiple sclerosis. We are very excited about the potential of this new, first-in-class treatment to prevent disease progression and inhibit demyelination in MS." About Quantum Biopharma Ltd. Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum Biopharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum Biopharma invented unbuzzd and spun out its OTC (over-the-counter) version to a company, Celly Nutrition Corp., now Unbuzzd Wellness Inc., led by industry veterans. Quantum Biopharma retains ownership of 19.86 per cent as of Sept. 30, 2025, of Unbuzzd Wellness. The agreement with Unbuzzd Wellness also includes royalty payments of 7 per cent of sales from unbuzzd until payments to Quantum Biopharma total $250-million. Once $250-million is reached, the royalty drops to 3 per cent in perpetuity. Quantum Biopharma retains 100 per cent of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum Biopharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. We seek Safe Harbor.